Thank you sir, good information. Please upload vedio on mock recall procedure and documentation.
@pharmalearners3120 Жыл бұрын
Mock recall generally be carried out for at least one batch of any product, dispatched for sale where maximum distributors are involved, to test the effectiveness of the arrangements of recall. The effectiveness of the recall procedure can also be checked by ‘evaluation of a real recall’. During mock recall, traceability shall be performed for at least, one of the raw materials used in the batches identified for mock recall. Mock Recall shall be performed at least once for the longest distribution chain and whenever a distributor/marketing company changes. Records of such mock recalls should be maintained by the QA Head of the company.
@SmileeAnil211314 жыл бұрын
Please clarify...when MC is received, investigated and we found the root cause and complete investigation is sent to customer and the customer is not accepted the response due to lacking of investigation and he is informed us to return back material, in that time shall we raise recall a note to recall material from that concerned customer.....
@aparajita35124 жыл бұрын
Please upload all lectures related to drug regulatory affairs
@aparajita35124 жыл бұрын
Please upload all topics related to drug regulatory affairs
@vinjamoorishivakumarreddy18224 жыл бұрын
Hello sir please do some vedios on instruments used in industry
@mostafizurrahaman10814 жыл бұрын
Like your content, but 2.11 mins, you said Ranitidine Recall in Sep 2020, which is 5 months after your video upload! please, be clear when you present information.
@gerikjini49484 жыл бұрын
Yeah... he has written on his 1st slide stating RANITIDINE RECALL in APRIL 2020, but at 2.11 mins. he read/said as SEPTEMBER 2020. May be slip of tongue/by mistake. AND further He said VIOX RECALL in SEPTEMBER 2004
@kiransanduri3 жыл бұрын
Class 1 recall and statuary recall
@gerikjini49484 жыл бұрын
Answer 1) CLASS I Answer 2) VOLUNTARY RECALL
@aparajita35124 жыл бұрын
I am pursuing pg diploma in drugs regulatory affairs